Elite Pharmaceuticals, Inc. Awarded Second U.S. Patent for Abuse Resistant Drug Formulation

Published: Apr 23, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NORTHVALE, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" by the United States Patent and Trademark Office. This is the second issued U.S. patent covering Elite's abuse resistant technology for opioid products. Elite has additional patents pending in the U.S., Canada and Europe.

Help employers find you! Check out all the jobs and post your resume.

Back to news